News for PTC Therapeutics, Inc. (PTCT)

PR NewswireWARREN, N.J., March 28, 2025 WARREN, N.J., March 28, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 24

PR NewswireWARREN, N.J., March 28, 2025 WARREN, N.J., March 28, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Europea

PTC Therapeutics Inc (PTCT) announced on March 20, 2025, the latest data from its Phase 3 APHENITY trial and subsequent open-label extension study, presented at

PR NewswireWARREN, N.J., March 20, 2025 ”” Results show 97% of phenylalanine (Phe) tolerance study participants were able to increase their dietary Phe in

PTC Therapeutics could boost revenue with vatiquinone for Friedreich's ataxia. Find out why PTCT stock is poised for growth with upcoming FDA reviews.

On March 4, 2025, Allan Jacobson, Director at PTC Therapeutics Inc (PTCT), sold 1,230 shares of the company, as reported in a SEC Filing. Following this transac

Fourth Quarter Revenue: $213 million.Full Year 2024 Revenue: $807 million, exceeding guidance.Cash Position: Over $1.1 billion at year-end 2024, plus an additi

PTC Therapeutics Inc's innovative approach to rare disorders positions it as a leader in RNA biology therapeutics.Despite robust product offerings, regulatory

Feb 27, 2025 / 09:30PM GMTOperator Ladies and gentlemen, thank you for standing by. Welcome to the PTC Therapeutics fourth quarter and full year 2024 earnings c

Although the revenue and EPS for PTC Therapeutics (PTCT) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of 75% and 3.96%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics Inc (PTCT) announced its financial results for the fourth quarter and full year of 2024, reporting a total revenue of $807 million, surpassing

PR NewswireWARREN, N.J., Feb. 27, 2025 ”“ Full year 2024 revenue of $807 million, exceeding guidance ”“ ”“ All 2024 clinical and regulatory milestones w

Quarterly Revenue: $213 million, falling short of the estimated $232.44 million.Full Year Revenue: $807 million, slightly below the annual estimate of $811.63

PTC Therapeutics Inc (PTCT) is set to release its Q4 2024 earnings on Feb 27, 2025. The consensus estimate for Q4 2024 revenue is $232.44 million, and the earni

Besides Wall Street's top -and-bottom-line estimates for PTC Therapeutics (PTCT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Transaction Overview On December 31, 2024, ARMISTICE CAPITAL, LLC (Trades, Portfolio) executed a strategic transaction involving Travere Therapeutics Inc (TVTX)

Transaction Overview On December 31, 2024, ARMISTICE CAPITAL, LLC (Trades, Portfolio), a notable investment firm, executed a strategic stock transaction by acqu